Gillison ML, et al. - Between June 9, 2011, and July 31, 2014, authors examined 987 subjects to assess the impact of cetuximab on patients' survival and its impact on acute and late toxicity in subjects with human papillomavirus (HPV)-positive oropharyngeal carcinoma. Inclusion criteria was histologically confirmed HPV-positive oropharyngeal carcinoma; American Joint Committee on Cancer 7th edition clinical categories T1–T2, N2a–N3 M0 or T3–T4, N0–N3 M0; Zubrod performance status 0 or 1; age not less than 18 years; and enough bone marrow, hepatic, and renal function, under the eligibility criteria. They observed inferior overall survival and progression-free survival in radiotherapy plus cetuximab vs radiotherapy plus cisplatin, which was validated as the standard of care for cases with HPV-positive oropharyngeal carcinoma.